Cargando…
Investigation of mesalazine as an antifibrotic drug following myocardial infarction in male mice
OBJECTIVES: Myocardial infarction (MI) initiates a complex reparative response during which damaged cardiac muscle is replaced by connective tissue. While the initial repair is essential for survival, excessive fibrosis post‐MI is a primary contributor to progressive cardiac dysfunction, and ultimat...
Autores principales: | Künzel, Stephan R., Winter, Luise, Hoffmann, Maximilian, Kant, Theresa A., Thiel, Jessica, Kronstein‐Wiedemann, Romy, Klapproth, Erik, Lorenz, Kristina, El‐Armouche, Ali, Kämmerer, Susanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492006/ https://www.ncbi.nlm.nih.gov/pubmed/37688424 http://dx.doi.org/10.14814/phy2.15809 |
Ejemplares similares
-
Repurposing mesalazine against cardiac fibrosis in vitro
por: Hoffmann, Maximilian, et al.
Publicado: (2020) -
Systemic mesalazine treatment prevents spontaneous skin fibrosis in PLK2-deficient mice
por: Newe, Manja, et al.
Publicado: (2021) -
Genetic Deletion of Polo-Like Kinase 2 Induces a Pro-Fibrotic Pulmonary Phenotype
por: Kant, Theresa A., et al.
Publicado: (2021) -
Targeting cardiomyocyte ADAM10 ectodomain shedding promotes survival early after myocardial infarction
por: Klapproth, Erik, et al.
Publicado: (2022) -
Modeling atrial fibrosis in vitro—Generation and characterization of a novel human atrial fibroblast cell line
por: Künzel, Stephan R., et al.
Publicado: (2020)